These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1617242)

  • 21. Bayesian Methods in Human Drug and Biological Products Development in CDER and CBER.
    Ionan AC; Clark J; Travis J; Amatya A; Scott J; Smith JP; Chattopadhyay S; Salerno MJ; Rothmann M
    Ther Innov Regul Sci; 2023 May; 57(3):436-444. PubMed ID: 36459346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Operation of a radiopharmacy for a clinical trial.
    Norenberg JP; Petry NA; Schwarz S
    Semin Nucl Med; 2010 Sep; 40(5):347-56. PubMed ID: 20674594
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2005 Donor Eligibility Requirements: Unintended Consequences for Stem Cell Development.
    Couture LA; Carpenter MK
    Stem Cells Transl Med; 2015 Oct; 4(10):1097-100. PubMed ID: 26285658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. US definitions, current use, and FDA stance on use of platelet-rich plasma in sports medicine.
    Beitzel K; Allen D; Apostolakos J; Russell RP; McCarthy MB; Gallo GJ; Cote MP; Mazzocca AD
    J Knee Surg; 2015 Feb; 28(1):29-34. PubMed ID: 25268794
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eyes on the Prize: Decoding the Ophthalmic Product Regulations and Intricacies of the U.S. Food and Drug Administration Approval.
    Hirani K; Bansinath M; Mittal R; Lemos JRN; Adis E; Poojari P; Igoe JM; Soares MR; Bhattacharya S; Weiss RE
    J Ocul Pharmacol Ther; 2023 Oct; 39(8):572-582. PubMed ID: 37797226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Off-label use of medical products in radiation therapy: summary of the report of AAPM Task Group No. 121.
    Thomadsen BR; Heaton HT; Jani SK; Masten JP; Napolitano ME; Ouhib Z; Reft CS; Rivard MJ; Robin TT; Subramanian M; Suleiman OH
    Med Phys; 2010 May; 37(5):2300-11. PubMed ID: 20527564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulating biopharmaceuticals under CDER versus CBER: an insider's perspective.
    Schwieterman WD
    Drug Discov Today; 2006 Oct; 11(19-20):945-51. PubMed ID: 16997146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine INDs: review of clinical holds.
    Miller DL; Ross JJ
    Vaccine; 2005 Jan; 23(9):1099-101. PubMed ID: 15629351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulatory administrative databases in FDA's Center for Biologics Evaluation and Research: convergence toward a unified database.
    Smith JK
    AAPS J; 2013 Apr; 15(2):388-94. PubMed ID: 23269527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory considerations for nucleic acid vaccines.
    Smith HA
    Vaccine; 1994 Dec; 12(16):1515-9. PubMed ID: 7879416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulatory considerations in vaccine design.
    Davenport LW
    Pharm Biotechnol; 1995; 6():81-96. PubMed ID: 7551250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Revision of the requirements for constituent materials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2011 Apr; 76(71):20513-8. PubMed ID: 21491807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Topical delivery of cultured stem cells to human non-healing wounds: GMP facility development in an academic setting and FDA requirements for an IND and human testing.
    Yufit T; Carson P; Falanga V
    Curr Drug Deliv; 2014; 11(5):572-81. PubMed ID: 23517627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. US FDA review and regulation of preventive vaccines for infectious disease indications: impact of the FDA Amendments Act 2007.
    Gruber MF
    Expert Rev Vaccines; 2011 Jul; 10(7):1011-9. PubMed ID: 21806396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The IND application.
    Ferkany JW; Williams M
    Curr Protoc Pharmacol; 2008 Sep; Chapter 9():Unit 9.10. PubMed ID: 22294234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA gene rules impractical.
    Morrison C
    Nat Biotechnol; 2001 Jan; 19(1):5. PubMed ID: 11135515
    [No Abstract]   [Full Text] [Related]  

  • 40. The 21 CFR (Code of Federal Regulations) online database: Food and Drug Administration regulations full-text.
    Bobka MS
    Med Ref Serv Q; 1993; 12(1):7-15. PubMed ID: 10126251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.